Evoke Pharma (EVOK)
(Delayed Data from NSDQ)
$5.25 USD
+0.05 (0.96%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $5.14 -0.11 (-2.10%) 7:24 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.25 USD
+0.05 (0.96%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $5.14 -0.11 (-2.10%) 7:24 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Evoke Pharma, Inc. (EVOK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Evoke Pharma, Inc. (EVOK) delivered earnings and revenue surprises of -125.00% and -98.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Evoke Pharma (EVOK) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Evoke Pharma (EVOK) stock based on the movements in the options market lately.
New Strong Sell Stocks for August 24th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance
by Zacks Equity Research
The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.
Foamix Initiates Phase II Study on Acne Combination Foam
by Zacks Equity Research
Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.
Zynerba Releases Data on Epilepsy Candidate, Stock Down
by Zacks Equity Research
Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.
Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs
by Zacks Equity Research
Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.
Generic-Drugs Stock Outlook: No Respite from Pricing Issues
by Zacks Equity Research
Generic drugmakers, in general, are having a rather poor year, primarily due to ongoing pricing pressure and rising competition.
Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead
by Ekta Bagri
Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.
Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA
by Zacks Equity Research
The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.
Falling Earnings Estimates Signal Weakness Ahead for Amphastar (AMPH)
by Zacks Equity Research
Amphastar (AMPH) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.
Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III
by Zacks Equity Research
Pharma, Inc. (EVOK) announced additional data from a phase III trial on Gimoti (nasal delivery), a novel formulation of its marketed drug, metoclopramide, for diabetic gastroparesis in adult women.
Company News for December 19, 2016
by Zacks Equity Research
Companies in the News are: NFLX,AMZN,EGLT,EVOK,JBL
3 Healthcare Stocks Poised to Beat Q2 Earnings
by Zacks Equity Research
in the second quarter, results have managed to outpace expectations so far.